Despite outcome improvements for acute lymphoblastic leukemia (ALL), mortality rates remain high, with significant survival disparities seen between Black and White children.
Five-year survival data show that despite outcome improvements for acute lymphoblastic leukemia (ALL), mortality rates remain high, with significant survival disparities seen between Black and White children, detail study findings published in Cureus.
ALL is the most common childhood cancer—with survival rates that exceed 90%.
“Whether race/ethnicity affects the survival rate of ALL and by how much has been the topic of the question with mixed results among different studies and clinical centers,” they said. “Our study explored the survival rate differences between Black and White children diagnosed with ALL to make steps towards providing equal and unbiased care for every child diagnosed.”
The authors conducted a retrospective analysis on 17,663 cases of ALL seen among 1425 Black and 16,238 White children between 1975 and 2016, using data from the Surveillance, Epidemiology, and End Results (SEER) Program database on children aged 0 to 19 years. They used adjusted and unadjusted multivariate Cox regression analysis to delineate a possible link between race and 5-year survival, dividing their study population into 4 age groups (1-4, 5-9, 10-14, 15-19 years) and 4 time periods (1975-1984, 1985-1994, 1995-2004, 2005-2016).
Overall data demonstrate a greater prevalence of 5-year survival in the White children compared with the Black children (P < .001), for the unadjusted and adjusted analyses. This conclusion can be seen in the following results:
There were close to equal sex rates between the groups (Black: 56.4% male, 43.7% female; White: 56.6% male, 43.4% female), but more Black children aged 1 to 4 years (47.7% vs 41.5%; P < .001). White children, however, had more instances of B-cell leukemia, with 95.1% compared with 89.7% seen among Black children (P < .001).
Additional analyses produced these results:
“Our study supported that there continues to be a significant difference in the five-year survival rate between Black and White children diagnosed with ALL,” the authors concluded. “Additionally, the rate at which children die is significantly higher in Black children. Sex, age, and year of diagnosis are important confounding variables, but even when controlled for, did not eliminate the difference in survival rates.”
Possible limitations on their findings may have come from the lack of SEER data on socioeconomic status, health care access, genetic risk factors, comorbidities, disease-specific treatment, and relapse. In addition, they were unable to account for cancer grade, having focused on ALL.
The authors recommend that future studies control for more confounders, as well as continue to investigate the contribution of access, or lack thereof, to health care by building on prior research. For this, they highlight St. Jude Children’s Research Hospital and a study that showed comparable survival rates—no matter the cancer type—between Black and White children specifically treated at the institution, which provides care regardless of ability to pay.
Reference
Bryant C, Mayhew M, Fleites J, Lozano J, Saunders JM. Comparison of five-year survival rate between Black and White children with acute lymphoblastic leukemia. Cureus. Published online November 30, 2020. doi:10.7759/cureus.11797
Obesity at Cancer Diagnosis Linked to Worse Survival Outcomes in Pediatric Patients
January 13th 2025Pediatric patients considered obese at cancer diagnosis are linked to significantly worse survival outcomes, especially those with acute lymphoblastic leukemia and central nervous system tumors.
Read More
Lymphoma Research Foundation CEO on Biden’s Cancer Moonshot, Financial Toxicity
February 3rd 2022On this episode of Managed Care Cast, we speak with Meghan Gutierrez, CEO of the Lymphoma Research Foundation, about financial toxicity, how the pandemic has affected patients’ financial needs when they have cancer, health care disparities and care gaps, and more.
Listen
Zanubrutinib Plus Obinutuzumab Granted Accelerated FDA Approval for R/R Follicular Lymphoma
March 7th 2024The FDA granted accelerated approval to combination zanubrutinib and obinutuzumab for the treatment of relapsed or refractory (R/R) follicular lymphoma following 2 or more lines of therapy.
Read More
Keeping Patients With Cancer Out of the ED Through Dedicated Urgent Care
October 13th 2021On this episode of Managed Care Cast, we bring you an interview conducted by the editorial director of OncLive® who talks with the advance practice provider chief at Winship Cancer Institute about how having a dedicated cancer urgent care center will make cancer treatment plans seamless whil helping patients avoid exposure to infectious diseases in emergency department waiting rooms.
Listen
ICYMI: Highlights From ASH 2023
December 20th 2023The most-read content from the 2023 American Society of Hematology Annual Meeting and Exposition included the latest in treating hematologic malignancies, the hope brought by novel therapy strategies, and the potential for artificial intelligence to improve diagnostic accuracy.
Read More
Zanubrutinib May Be Viable Option After Acalabrutinib Intolerance in B-Cell Malignancies
December 11th 2023Patients with B-cell malignancies who were intolerant to treatment with acalabrutinib experienced clinically meaningful benefits when treated with zanubrutinib, suggesting zanubrutinib may be a viable treatment option for this population.
Read More